Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer

PURPOSE: AZD1775 (adavosertib) is an inhibitor of the Wee1 kinase. In this study, we built on our preclinical studies to evaluate the safety and efficacy of AZD1775 in combination with gemcitabine and radiation in patients with newly diagnosed locally advanced pancreatic cancer. PATIENTS AND METHODS...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Cuneo, Kyle C., Morgan, Meredith A., Sahai, Vaibhav, Schipper, Matthew J., Parsels, Leslie A., Parsels, Joshua D., Devasia, Theresa, Al-Hawaray, Mahmoud, Cho, Clifford S., Nathan, Hari, Maybaum, Jonathan, Zalupski, Mark M., Lawrence, Theodore S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2019
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006846/
https://ncbi.nlm.nih.gov/pubmed/31398082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00730
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia